OTraces’ TME Cancer Blood Test Presentation at Innovation Challenge Spurs Investor Interest from JP Morgan Healthcare Conference Participants
January 11, 2018 13:39 ET
|
OTraces, Inc.
SAN FRANCISCO and BALTIMORE, Jan. 11, 2018 (GLOBE NEWSWIRE) -- OTraces Inc., a Sykesville, Maryland-based cancer diagnostics company with a unique patented and patent-pending blood test which...
Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose
January 08, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced initial safety data...
Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company
January 08, 2018 08:00 ET
|
Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has...